EGFR Tyrosine Kinase Inhibitor Monotherapy Should Remain the Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC. Stock-Martineau S, Shepherd FA. J Thorac Oncol 2021;16:1793-1797.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Stock-Martineau S, Shepherd FA. EGFR Tyrosine Kinase Inhibitor Monotherapy Should Remain the Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC. J Thorac Oncol 2021;16:1793-1797.
PMID: 34716003